One platform,
from target to clinic.
We use our competitive advantage in antibody drug creation to build an internal pipeline of differentiated assets.
Address unmet need across indications.
With platforms designed to address complex target types and modalities, we look broadly for ideas with the highest potential impact for patients, without constraint by therapeutic area.
We select programs based on:
The science.
The unmet need.
The opportunity for differentiation.
The path to the clinic.
Find antibodies with drug-like properties.
Behind every program in our pipeline is a single immune cell that produced an antibody designed by nature to treat disease.
We induce robust immune responses and search them deeply using our proprietary single-cell screening technology. We assess hundreds of antibodies at high-throughput, progress multiple high-quality candidates through engineering and optimization, and select those with the properties needed to become new medicines.
Turn antibodies into potential medicines.
We integrate development expertise early into the discovery process to select and move candidates efficiently through IND-enabling studies.
With Discovery, Translational Science, Development, and TechOps under one roof, we work cross-functionally to advance the most potent, manufacturable candidates towards the clinic.
Make investigational medicines.
We’re bringing clinical manufacturing in-house to enable efficient tech transfer, flexible timelines, and processes customized for challenging modalities.
Our Vancouver-based 124,000 sqft clinical manufacturing facility has capabilities for GMP cell banking and production of GMP drug substance (up to 2,000 L bioreactors), is set to be online in 2025.
Bring medicines to patients.
We’re advancing programs to address unmet medical need in autoimmunity, endocrine and metabolic conditions, and beyond.
Our first two programs, ABCL635 and ABCL575, are anticipated to enter Phase I clinical trials in 2025.
Expand the reach of antibody therapeutics.
Antibodies for hard-to-treat cancers.
We design and engineer T-cell engagers to address challenging tumor types by incorporating novel CD3, co-stimulatory, and multispecific modalities.
First-in-class antibody medicines.
We are using our platform to develop first-in-class antibody medicines for well-validated complex transmembrane protein targets that have been intractable using traditional approaches.
Rapid treatments for emerging viruses.
We developed a pandemic response platform with DARPA, part of the US Department of Defense, and in collaboration with our partner Eli Lilly, brought two antibody medicines to the clinic to combat COVID-19.
